V
Vera Hirsh
Researcher at McGill University
Publications - 153
Citations - 20710
Vera Hirsh is an academic researcher from McGill University. The author has contributed to research in topics: Lung cancer & Afatinib. The author has an hindex of 41, co-authored 151 publications receiving 19287 citations. Previous affiliations of Vera Hirsh include University of Alberta.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Martin Reck,Joachim von Pawel,Petr Zatloukal,Rodryg Ramlau,Vera Gorbounova,Vera Hirsh,Natasha B. Leighl,J. Mezger,Venice Archer,Nicola Moore,Christian Manegold +10 more
TL;DR: Combining bevacizumab (7.5 or 15 mg/kg) with CG significantly improved PFS and objective response rate and offers clinical benefit for bevicizumAB-eligible patients with advanced NSCLC.
Journal ArticleDOI
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry,Luis Costa,François Goldwasser,Vera Hirsh,Vania Hungria,Jana Prausova,Giorgio V. Scagliotti,Harm Sleeboom,Andrew Spencer,Saroj Vadhan-Raj,Roger von Moos,Wolfgang Willenbacher,Penella J. Woll,Jianming Wang,Qi Jiang,Susie Jun,Roger Dansey,Howard S. Yeh +17 more
TL;DR: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Journal ArticleDOI
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller,Vincent A. Miller,Vera Hirsh,Jacques Cadranel,Yuh Min Chen,Keunchil Park,Sang We Kim,Caicun Zhou,Wu Chou Su,M. Wang,Yan Sun,Dae Seog Heo,Lucio Crinò,Eng Huat Tan,Tsu Yi Chao,Mehdi Shahidi,X.J. Cong,Robert M. Lorence,James Chih-Hsin Yang +18 more
TL;DR: The findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.